Linking therapeutically active molecules to specific antibodies can help to pilot them to their designated targets and minimize side effects -- especially when treating tumors. Scientists have now described novel conjugates made from antibodies and a kinesin spindle protein inhibitor. Changing the linker between the two components allows for tuning the activity of this cytostatic drug, which is effective against a broad palette of cancers.